ATR vs. PFE: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ATR and PFE, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
PFE’s market capitalization of 144.29 billion USD is significantly greater than ATR’s 10.64 billion USD, highlighting its more substantial market valuation.
With betas of 0.59 for ATR and 0.49 for PFE, both stocks show similar sensitivity to overall market movements.
| Symbol | ATR | PFE |
|---|---|---|
| Company Name | AptarGroup, Inc. | Pfizer Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Instruments & Supplies | Drug Manufacturers - General |
| CEO | Stephan B. Tanda | Albert Bourla |
| Price | 161.04 USD | 25.38 USD |
| Market Cap | 10.64 billion USD | 144.29 billion USD |
| Beta | 0.59 | 0.49 |
| Exchange | NYSE | NYSE |
| IPO Date | April 23, 1993 | June 1, 1972 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ATR and PFE by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ATR
14.87%
Medical - Instruments & Supplies Industry
- Max
- 26.65%
- Q3
- 13.00%
- Median
- 1.08%
- Q1
- -8.11%
- Min
- -38.20%
In the upper quartile for the Medical - Instruments & Supplies industry, ATR’s Return on Equity of 14.87% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
PFE
8.78%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
PFE’s Return on Equity of 8.78% is in the lower quartile for the Drug Manufacturers - General industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
Return on Invested Capital
ATR
11.90%
Medical - Instruments & Supplies Industry
- Max
- 20.14%
- Q3
- 7.36%
- Median
- 1.97%
- Q1
- -6.22%
- Min
- -20.00%
In the upper quartile for the Medical - Instruments & Supplies industry, ATR’s Return on Invested Capital of 11.90% signifies a highly effective use of its capital to generate profits when compared to its peers.
PFE
8.97%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
PFE’s Return on Invested Capital of 8.97% is in the lower quartile for the Drug Manufacturers - General industry. This indicates a less efficient conversion of invested capital into profit compared to most of its competitors.
Net Profit Margin
ATR
10.42%
Medical - Instruments & Supplies Industry
- Max
- 28.95%
- Q3
- 11.24%
- Median
- -2.83%
- Q1
- -12.85%
- Min
- -26.41%
ATR’s Net Profit Margin of 10.42% is aligned with the median group of its peers in the Medical - Instruments & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
PFE
12.59%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
PFE’s Net Profit Margin of 12.59% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
ATR
14.17%
Medical - Instruments & Supplies Industry
- Max
- 32.10%
- Q3
- 16.03%
- Median
- 2.28%
- Q1
- -7.96%
- Min
- -26.84%
ATR’s Operating Profit Margin of 14.17% is around the midpoint for the Medical - Instruments & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
PFE
23.65%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
PFE’s Operating Profit Margin of 23.65% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ATR | PFE |
|---|---|---|
| Return on Equity (TTM) | 14.87% | 8.78% |
| Return on Assets (TTM) | 8.18% | 3.78% |
| Return on Invested Capital (TTM) | 11.90% | 8.97% |
| Net Profit Margin (TTM) | 10.42% | 12.59% |
| Operating Profit Margin (TTM) | 14.17% | 23.65% |
| Gross Profit Margin (TTM) | 36.41% | 67.39% |
Financial Strength
Current Ratio
ATR
1.25
Medical - Instruments & Supplies Industry
- Max
- 6.79
- Q3
- 4.57
- Median
- 2.64
- Q1
- 1.81
- Min
- 1.10
ATR’s Current Ratio of 1.25 falls into the lower quartile for the Medical - Instruments & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
PFE
1.26
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
PFE’s Current Ratio of 1.26 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ATR
0.41
Medical - Instruments & Supplies Industry
- Max
- 1.46
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.16
- Min
- 0.03
ATR’s Debt-to-Equity Ratio of 0.41 is typical for the Medical - Instruments & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
PFE
0.68
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
PFE’s Debt-to-Equity Ratio of 0.68 is typical for the Drug Manufacturers - General industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
ATR
11.17
Medical - Instruments & Supplies Industry
- Max
- 25.04
- Q3
- 8.80
- Median
- 3.66
- Q1
- -3.85
- Min
- -11.93
ATR’s Interest Coverage Ratio of 11.17 is in the upper quartile for the Medical - Instruments & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
PFE
5.00
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
PFE’s Interest Coverage Ratio of 5.00 is positioned comfortably within the norm for the Drug Manufacturers - General industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ATR | PFE |
|---|---|---|
| Current Ratio (TTM) | 1.25 | 1.26 |
| Quick Ratio (TTM) | 0.85 | 0.96 |
| Debt-to-Equity Ratio (TTM) | 0.41 | 0.68 |
| Debt-to-Asset Ratio (TTM) | 0.23 | 0.29 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.19 | 3.47 |
| Interest Coverage Ratio (TTM) | 11.17 | 5.00 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ATR and PFE. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ATR
1.12%
Medical - Instruments & Supplies Industry
- Max
- 4.02%
- Q3
- 0.38%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 1.12%, ATR offers a more attractive income stream than most of its peers in the Medical - Instruments & Supplies industry, signaling a strong commitment to shareholder returns.
PFE
6.70%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
With a Dividend Yield of 6.70%, PFE offers a more attractive income stream than most of its peers in the Drug Manufacturers - General industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
ATR
31.58%
Medical - Instruments & Supplies Industry
- Max
- 76.77%
- Q3
- 11.37%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ATR’s Dividend Payout Ratio of 31.58% is in the upper quartile for the Medical - Instruments & Supplies industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
PFE
121.75%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
PFE’s Dividend Payout Ratio of 121.75% is above 100%. This means the company is paying out more in dividends than it earned, a practice that is often unsustainable and could indicate a risk to future dividend stability.
Dividend at a Glance
| Symbol | ATR | PFE |
|---|---|---|
| Dividend Yield (TTM) | 1.12% | 6.70% |
| Dividend Payout Ratio (TTM) | 31.58% | 121.75% |
Valuation
Price-to-Earnings Ratio
ATR
28.83
Medical - Instruments & Supplies Industry
- Max
- 45.65
- Q3
- 44.10
- Median
- 35.47
- Q1
- 29.60
- Min
- 21.65
In the lower quartile for the Medical - Instruments & Supplies industry, ATR’s P/E Ratio of 28.83 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
PFE
18.31
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
PFE’s P/E Ratio of 18.31 is within the middle range for the Drug Manufacturers - General industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ATR
2.54
Medical - Instruments & Supplies Industry
- Max
- 5.80
- Q3
- 3.68
- Median
- 2.56
- Q1
- 1.87
- Min
- 0.22
ATR’s Forward PEG Ratio of 2.54 is within the middle range of its peers in the Medical - Instruments & Supplies industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
PFE
-3.86
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
PFE has a negative Forward PEG Ratio of -3.86. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
Price-to-Sales Ratio
ATR
2.99
Medical - Instruments & Supplies Industry
- Max
- 12.87
- Q3
- 6.95
- Median
- 3.45
- Q1
- 2.24
- Min
- 0.71
ATR’s P/S Ratio of 2.99 aligns with the market consensus for the Medical - Instruments & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
PFE
2.31
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
PFE’s P/S Ratio of 2.31 aligns with the market consensus for the Drug Manufacturers - General industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
ATR
4.18
Medical - Instruments & Supplies Industry
- Max
- 9.60
- Q3
- 5.48
- Median
- 3.37
- Q1
- 1.95
- Min
- 0.65
ATR’s P/B Ratio of 4.18 is within the conventional range for the Medical - Instruments & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
PFE
1.59
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
Valuation at a Glance
| Symbol | ATR | PFE |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 28.83 | 18.31 |
| Forward PEG Ratio (TTM) | 2.54 | -3.86 |
| Price-to-Sales Ratio (P/S, TTM) | 2.99 | 2.31 |
| Price-to-Book Ratio (P/B, TTM) | 4.18 | 1.59 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 29.67 | 12.86 |
| EV-to-EBITDA (TTM) | 14.80 | 11.85 |
| EV-to-Sales (TTM) | 3.25 | 3.27 |